H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Tyra Biosciences (TYRA) to $45 from $30 and keeps a Buy rating on the shares. The firm says the Phase 3 infigratinib data “risk-mitigate” the oral FGFR inhibitor thesis and improve dabogratinib’s outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Buy Rating on Tyra Biosciences Driven by Dabogratinib’s Differentiated FGFR3 Profile and Key Near-Term Phase II Catalyst
- Tyra Biosciences Advances TYRA-300 Bladder Cancer Trial: What Investors Should Watch
- Tyra Biosciences price target raised to $53 from $37 at Wedbush
- Tyra Biosciences participates in a coferejce call with William Blair
- Tyra Biosciences initiated with an Outperform at William Blair